Combinatorial targeting of a chromatin complex comprising Dot1L, menin and the tyrosine kinase BAZ1B reveals a new therapeutic vulnerability of endocrine therapy-resistant breast cancer

BACKGROUND: Targeting vulnerabilities of cancer cells by inhibiting key regulators of cell proliferation or survival represents a promising way to overcome resistance to current therapies. In breast cancer (BC), resistance to endocrine therapy results from constitutively active or aberrant estrogen...

Descripción completa

Detalles Bibliográficos
Autores principales: Salvati, Annamaria, Melone, Viola, Sellitto, Assunta, Rizzo, Francesca, Tarallo, Roberta, Nyman, Tuula A., Giurato, Giorgio, Nassa, Giovanni, Weisz, Alessandro
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2022
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9290241/
https://www.ncbi.nlm.nih.gov/pubmed/35850772
http://dx.doi.org/10.1186/s13058-022-01547-7

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9290241/
https://www.ncbi.nlm.nih.gov/pubmed/35850772
http://dx.doi.org/10.1186/s13058-022-01547-7

Ejemplares similares